Skip to main content

Advertisement

Table 4 Rates of adverse events

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Events/100 PY (95 % CI) Trimmed populationa Stratified-matched population
Rituximab Anti-TNF Ratio of Rituximab Anti-TNF Ratio of ratesb
(n = 265) (n = 737) ratesb (n = 205) (n = 205)
Cancer 1.5 (0.0, 3.0) 1.9 (0.8, 3.0) 0.8 (0.3, 2.3) 1.6 (0.5, 4.9) 2.9 (1.2, 7.0) 0.5 (0.1, 2.8)
Infection       
 All events 37.7 (29.9, 45.5) 41.0 (36.0, 46.0) 0.9 (0.7, 1.2) 38.1 (30.2, 48.0) 44.4 (35.4, 55.5) 0.9 (0.6, 1.2)
 Serious infections 1.2 (0.0, 2.7) 2.8 (1.3, 4.3) 0.4 (0.1, 1.3) 2.0 (0.7, 6.3) 4.5 (2.0, 10.0) 0.5 (0.1, 2.1)
 Cardiovascular 1.8 (0.2, 3.4) 1.4 (0.5, 2.4) 1.3 (0.4, 4.0) 1.6 (0.5, 4.9) 2.9 (1.2, 7.0) 0.5 (0.1, 2.8)
  1. aRates in the trimmed population were standardized by age and sex. Confidence intervals were calculated using a Poisson approximation of the standard error. bRatio of rituximab/anti-TNF agent rates. Anti-TNF anti–tumor necrosis factor, PY patient-years